Finanzen von ImageneBio Inc (IMA)IMAImageneBio Inc

Evaluating the bottom line, ImageneBio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -41.34%, provide a clear picture of how effectively IMA converts its operational activities into shareholder value.

In the context of the broader market, IMA competes directly with industry leaders such as ELOX and HRTX. With a market capitalization of $66.29M, it holds a leading position in the sector. When comparing efficiency, IMA's gross margin of N/A stands against ELOX's N/A and HRTX's 69.28%. Such benchmarking helps identify whether ImageneBio Inc is trading at a premium or discount relative to its financial performance.

The company has reported a total revenue of $800,000 in Q1 2025, but has consistently shown net losses, including a net loss of $10.6 million in Q1 2026. The gross margin was 100% in Q1 2025, but has since dropped to 0% in subsequent quarters, indicating potential operational issues.